-
Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01 Clinical Trial Not Allowed)
(PAR-19-357)
National Institute of Allergy and Infectious Diseases
National Heart, Lung, and Blood Institute
Application Receipt Date(s): January 8, 2020; January 8, 2021; January 10, 2022
All applications are due, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Planning Grant for Global Infectious Disease Research Training Program (D71 No Clinical Trials Allowed)
(PAR-19-362)
John E. Fogarty International Center
Application Receipt Date(s): November 12, 2019, October 28, 2020, October 28, 2021, October 28, 2022
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
(PAR-19-363)
National Cancer Institute
Application Receipt Date(s): Standard dates apply.
The first standard due date for this FOA is October 5, 2019
-
Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R21 Clinical Trial Not Allowed)
(PAR-19-364)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): January 8, 2020; January 8, 2021; January 10, 2022
All applications are due, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revision Applications for Mechanisms of Drug Resistance (R01 Clinical Trials Not Allowed)
(RFA-CA-19-049)
National Cancer Institute
Application Receipt Date(s): October 24, 2019; June 24, 2020; October 22, 2020, June 23, 2021.
No late applications will be accepted for this Funding Opportunity Announcement
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revision Applications for Mechanisms of Drug Resistance (U01 Clinical Trials Not Allowed)
(RFA-CA-19-050)
National Cancer Institute
Application Receipt Date(s): October 24, 2019; June 24, 2020; October 22, 2020, June 23, 2021.
No late applications will be accepted for this Funding Opportunity Announcement
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s)
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Revision Applications for Mechanisms of Drug Resistance (U54 Clinical Trials Not Allowed)
(RFA-CA-19-051)
National Cancer Institute
Application Receipt Date(s): October 24, 2019; June 24, 2020; October 22, 2020, June 23, 2021.
All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
No late applications will be accepted for this Funding Opportunity Announcement.
-
Revision Applications for Mechanisms of Drug Resistance (P01 Clinical Trials Not Allowed)
(RFA-CA-19-052)
National Cancer Institute
Application Receipt Date(s): October 24, 2019; June 24, 2020; October 22, 2020, June 23, 2021.
All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
No late applications will be accepted for this Funding Opportunity Announcement.
-
Revision Applications for Mechanisms of Drug Resistance (P50 Clinical Trials Not Allowed)
(RFA-CA-19-053)
National Cancer Institute
Application Receipt Date(s): October 24, 2019; June 24, 2020; October 22, 2020, June 23, 2021.
All applicants are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
No late applications will be accepted for this Funding Opportunity Announcement.
-
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
(RFA-DA-20-024)
National Institute on Drug Abuse
Application Receipt Date(s): November 15, 2019.
All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).
No late applications will be accepted for this Funding Opportunity Announcement.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Clinical Research Centers (U01 Clinical Trial Optional)
(RFA-DK-19-015)
National Institute of Diabetes and Digestive and Kidney Diseases
National Institute on Aging
Application Receipt Date(s): November 7, 2019
-
Prevention of Lower Urinary Tract Symptoms (PLUS) Research Consortium Scientific and Data Coordinating Center (U24 Clinical Trial Optional)
(RFA-DK-19-016)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): November 7, 2019
-
Using Archived Data and Specimen Collections to Advance Maternal and Pediatric HIV/AIDS Research (R21 Clinical Trial Not Allowed)
(RFA-HD-20-020)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): November 1, 2019
-
Trans-Agency Blood-Brain Interface Program (R61/R33 - Clinical Trials Not Allowed)
(RFA-HL-20-021)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): December 2, 2019, October 19, 2020, December 11, 2020
-
Mechanistic Basis of TDP-43-dependent Pathobiology in Common Dementias (R01 Clinical Trial not Allowed)
(RFA-NS-20-005)
National Institute of Neurological Disorders and Stroke
National Institute on Aging
Application Receipt Date(s): November 15, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
Peripheral Pathology in the Lewy Body Dementias (R01 Clinical Trial Not Allowed)
(RFA-NS-20-014)
National Institute of Neurological Disorders and Stroke
National Institute on Aging
Application Receipt Date(s): The due date for this FOA is December 3, 2019
No late applications will be accepted for this Funding Opportunity Announcement